ProKidney
Develops rilparencel for advanced chronic kidney disease and type 2 diabetes.
Something off on this page? Send us feedback.
Profile
Develops rilparencel, an autologous cell therapy in pivotal testing for advanced chronic kidney disease and type 2 diabetes. The program combines clinical development with manufacturing and quality operations, rather than marketed-product sales.
Rilparencel, also called REACT, is an autologous cell therapy in the PROACT 1 pivotal study for people with advanced chronic kidney disease and type 2 diabetes. The randomized, blinded, sham-controlled study evaluates a targeted patient population.
The program focuses on a U.S. registration pathway after discontinuing the overseas-focused PROACT 2. Rilparencel has FDA RMAT designation, and FDA alignment identifies eGFR slope in PROACT 1 as a potential surrogate endpoint for an accelerated-approval BLA submission.
Operations are development- and manufacturing-intensive rather than built around a marketed product. More than half of employees work in manufacturing, operations, or quality roles.
Rilparencel remains in clinical development. Its pathway depends on completing PROACT 1, the eGFR-slope result, and FDA action.
Company facts
Key statistics
Year to date −17.7% · Average volume (30d) 1.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Jun 30, 2025 | B of A Securities | Downgrade | Neutral | Underperform |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026Q2 FY26 | −$0.14 | −$0.15 | −7.1% | $186.3K | $150.0K | −19.5% | −8.07% |
| Aug 10, 2026Q2 FY26 | −$0.14 | −$0.15 | −7.1% | $186.3K | $150.0K | −19.5% | −4.73% |
| May 15, 2026Q1 FY26 | −$0.13 | −$0.14 | −7.7% | $100.3K | $226.0K | +125.4% | −3.01% |
| Mar 18, 2026Q4 FY25 | −$0.16 | −$0.14 | +12.5% | $600 | $223.0K | +37,066.7% | −6.25% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $230.0K | $221.0K | $217.0K | $225.0K | $226.0K | $150.0K | |
| Gross profit | $230.0K | $221.0K | $217.0K | −$1.2M | −$1.2M | $150.0K | |
| Operating income | −$41.4M | −$39.7M | −$38.5M | −$45.4M | −$44.9M | −$48.4M | |
| Net income | −$16.7M | −$16.6M | −$16.5M | −$19.2M | −$22.6M | −$28.4M | |
| Diluted EPS | −$0.13 | −$0.13 | −$0.12 | −$0.14 | −$0.16 | −$0.15 | |
| Gross margin | 100.0% | 100.0% | 100.0% | -544.0% | -535.0% | 100.0% | |
| Operating margin | -17,994.8% | -17,967.9% | -17,759.9% | -20,164.9% | -19,881.9% | -32,248.7% |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $76.0K · FY25 $893.0K
Balance sheet, Jun 30, 2026Cash & short-term investments $181.6M · Total debt $3.5M · Total assets $249.0M · Shareholders' equity −$883.5M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 148.17M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Control Empresarial de Capitales S.A. de C.V. · 10 percent owner, other: Add'l Rep. Persons-see Ex.99-1 | 147.69M | 99.68% | Form 4 | Apr 30, 2026 |
| Tolerantia, LLC | 106.90M | 36.50% | 13D | Jun 5, 2025 |
| Pablo G. Legorreta · director, 10 percent owner: | 106.90M | 72.15% | Form 4 | Jun 5, 2025 |
| Suvretta Capital Management, LLC | 12.34M | 8.33% | 13F | May 15, 2026 |
| Morgan Stanley | 8.96M | 6.04% | 13F | May 15, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 20, 2026 | Brian JG Pereira | director | −27,052 | $1.42 |
| Aug 19, 2026 | Brian JG Pereira | director | −250,000 | $1.44 |
| Aug 18, 2026 | Brian JG Pereira | director | −257,164 | $1.37 |
| Nov 13, 2025 | Brian JG Pereira | director | −54,333 | $2.37 |
| Nov 12, 2025 | Brian JG Pereira | director | −255,026 | $2.72 |
Peers
- Eli Lilly
Jardiance and tirzepatide target CKD-progression pathways.
- AstraZeneca (ADR)
Farxiga treats CKD in adults at risk of progression.
- Novo Nordisk (ADR)
Ozempic is approved to reduce kidney-disease risks in diabetic CKD.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ProKidney | $1.80 | −1.91% | $615.3M | — | — | 752.3 | −32.1% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| AstraZeneca (ADR) | $161.79 | −0.55% | $252.33B | 24.4 | 15.2 | 4.1 | +6.4% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| Median | 24.4 | 18.4 | 4.1 | +6.4% |